For the endometrial adenocarcinoma organoids, combined treatment with buparlisib (PI3K inhibitor) and olaparib (PARP inhibitor) was optimal when compared with other combination strategies. The gene discussed is PIK3CA; the disease is endometrium adenocarcinoma.